인문학
사회과학
자연과학
공학
의약학
농수해양학
예술체육학
복합학
DBpia AI
AI 에이전트
AI 아이디어
AI 리더
AI 뷰어
Citeasy
크롬 서지관리 다운로드
지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
초록·키워드
Those experimental animals that tend to develop primary malignancies as a result of direct exposures to synthetic cancer agents can very well represent early stages of human cancers as compared to transplanted as well as genetically engineered tumor models. Generally, malignant growth resulting due to cancer agents tends to undergo three phases: initiation, promotion, as well as progression. On the basis of genetic alteration, agents can be divided into genotoxgents as well as non-genotoxgents. Carcinogens that tend to be complete, incomplete, as well as specified towards a target organ are classified into the other categories. These agents can be found through environmental pollutants, meat products, food additives, as well as anticancer agents. The advantages associated with the primary models created in animals by using chemicals include relevance to human clinical models, ease of production, and efficiency. However, it is difficult to track these tumors in small animals without damaging their bodies. As in human models, they grow randomly concerning site, timing, and number in animal models too. Non-invasive application of magnetic resonance imaging techniques has however shown promise in the diagnosis and follow-up of these models of cancer. This is because there are a number of advantages associated with the use of the MRI technology, among them being that this technology does not carry the hazards of ionizing radiation. This review evaluates the unique translational utility of chemically induced primary cancer models, which, unlike traditional xenografts, allow for the study of the entire carcinogenic spectrum—from initiation to progression. The aim of this work is to highlight the novelty of these models in bridging the gap between toxicology and clinical pharmacology, specifically their role in validating non-invasive imaging biomarkers and screening chemopreventive agents—such as Rapamycin and Resveratrol—currently under clinical investigation. By integrating these models with advanced MRI techniques, researchers can achieve more accurate preclinical staging and treatment monitoring. Ultimately, we argue that these models are essential for the development of targeted therapies and diagnostic agents that more faithfully replicate the sporadic nature of human clinical oncology.
인공지능 문자 인식 모델을 통해 추출된 텍스트로, 일부 오타나 오류가 포함될 수 있으나 지속적으로 개선 중입니다.
오류를 발견하셨다면 해당 부분을 드래그한 후 ' 를 통해 신고해주세요.
오류를 발견하셨다면 해당 부분을 드래그한 후 ' 를 통해 신고해주세요.
최근 본 자료 전체보기
